Dashboard
1
With ROE of 15.58%, it has a very attractive valuation with a 2.65 Price to Book Value
- Over the past year, while the stock has generated a return of 14.65%, its profits have risen by 16.8% ; the PEG ratio of the company is 1
- At the current price, the company has a high dividend yield of 3.6
Stock DNA
Pharmaceuticals & Biotechnology
CNY 19,460 Million (Large Cap)
17.00
NA
3.63%
0.46
15.58%
2.65
Revenue and Profits:
Net Sales:
6,539 Million
(Quarterly Results - Jun 2025)
Net Profit:
359 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
5.85%
0%
5.85%
6 Months
2.28%
0%
2.28%
1 Year
14.65%
0%
14.65%
2 Years
-31.08%
0%
-31.08%
3 Years
-59.83%
0%
-59.83%
4 Years
-47.26%
0%
-47.26%
5 Years
-78.92%
0%
-78.92%
DaShenLin Pharmaceutical Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
15.77%
EBIT Growth (5y)
6.86%
EBIT to Interest (avg)
9.90
Debt to EBITDA (avg)
0.81
Net Debt to Equity (avg)
0.49
Sales to Capital Employed (avg)
1.64
Tax Ratio
27.74%
Dividend Payout Ratio
77.00%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
17.12%
ROE (avg)
16.57%
Valuation key factors
Factor
Value
P/E Ratio
17
Industry P/E
Price to Book Value
2.65
EV to EBIT
13.94
EV to EBITDA
6.47
EV to Capital Employed
2.13
EV to Sales
0.86
PEG Ratio
1.01
Dividend Yield
3.63%
ROCE (Latest)
15.29%
ROE (Latest)
15.58%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
6,538.90
6,565.60
-0.41%
Operating Profit (PBDIT) excl Other Income
942.30
815.20
15.59%
Interest
50.40
61.60
-18.18%
Exceptional Items
1.20
-0.40
400.00%
Consolidate Net Profit
359.40
247.40
45.27%
Operating Profit Margin (Excl OI)
74.30%
54.60%
1.97%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -0.41% vs 9.00% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 45.27% vs -42.42% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
26,377.80
24,436.70
7.94%
Operating Profit (PBDIT) excl Other Income
3,424.70
3,474.50
-1.43%
Interest
282.30
275.30
2.54%
Exceptional Items
-13.10
14.20
-192.25%
Consolidate Net Profit
979.90
1,230.70
-20.38%
Operating Profit Margin (Excl OI)
58.00%
72.80%
-1.48%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 7.94% vs 15.44% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -20.38% vs 14.03% in Dec 2023
About DaShenLin Pharmaceutical Group Co., Ltd. 
DaShenLin Pharmaceutical Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






